TNBC is the most drug resistant subtype of breast cancer because of low or absent expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (Adams et al., 2019). This evidence concerns the gene ESR1 and breast carcinoma.